Physician profile

Jaida Taylor-Herring

St Petersburg, FL

NPI 1750360715

$424.29

in general payments reported to CMS, 2019-2025

5 companies · $69.02 in 2025

The $69.02 reported for 2025 was less than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$306.43

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Mayne Pharma Commercial LLC $121.84 2024
Evofem Biosciences, INC. $117.86 2022
Astellas Pharma US INC $115.57 2024 Veozah
Optumhealth Care Solutions, LLC $48.58 2025 Vivify Health Care Team Portal 001, Eitan Medical
Exeltis, USA INC. $20.44 2025 Slynd

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jaida Taylor-Herring

$424.29

in general payments reported 2019-2025

Years
2022-2025
Top company
Mayne Pharma Commercial LLC
Context
The $69.02 reported for 2025 was less than what a typical provider received nationally.

https://glasscript.com/doctor/11424688/jaida-taylor-herring

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.